ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.745,73
0,03%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. PDS Biotechnology Corporation (PDSB)

  7. PDS Biotechnology Corporation (PDSB) News

PDSB

PDS Biotechnology (PDSB)

PDS Biotechnology Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PDSB
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202423h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PDSBPDS Biotechnology Corporation
15/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
08/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
23/01/202422h31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PDSBPDS Biotechnology Corporation
22/01/202423h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
22/01/202422h45GlobeNewswire Inc.PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical OfficerNASDAQ:PDSBPDS Biotechnology Corporation
16/01/202414h00GlobeNewswire Inc.PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
04/12/202322h50GlobeNewswire Inc.PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PDSBPDS Biotechnology Corporation
04/12/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
28/11/202313h30GlobeNewswire Inc.PDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerNASDAQ:PDSBPDS Biotechnology Corporation
28/11/202312h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
14/11/202313h30GlobeNewswire Inc.PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PDSBPDS Biotechnology Corporation
09/11/202322h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
09/11/202314h00GlobeNewswire Inc.PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 MonthsNASDAQ:PDSBPDS Biotechnology Corporation
07/11/202314h00GlobeNewswire Inc.PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsNASDAQ:PDSBPDS Biotechnology Corporation
23/10/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
23/10/202314h00GlobeNewswire Inc.PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMONASDAQ:PDSBPDS Biotechnology Corporation
11/10/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
11/10/202314h00GlobeNewswire Inc.PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202322h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202322h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202315h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
03/10/202313h00GlobeNewswire Inc.PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:PDSBPDS Biotechnology Corporation
02/10/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
02/10/202314h00GlobeNewswire Inc.PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)NASDAQ:PDSBPDS Biotechnology Corporation
26/09/202314h00GlobeNewswire Inc.PDS Biotech to Present at the LD Micro Main Event XVINASDAQ:PDSBPDS Biotechnology Corporation
25/09/202314h00GlobeNewswire Inc.PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101NASDAQ:PDSBPDS Biotechnology Corporation
20/09/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PDSBPDS Biotechnology Corporation
20/09/202322h05GlobeNewswire Inc.PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:PDSBPDS Biotechnology Corporation
 Showing the most relevant articles for your search:NASDAQ:PDSB

Kürzlich von Ihnen besucht

COIN
SOLUSD
Solana
TG
RHM
Rheinmetall
DBI
SDXP
SDAX
TG
LHA
Deutsche Lufthansa
NASDAQ
TSLA
Tesla
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
AMEX
XLE
Energy Select Sector SPDR
COIN
ETHUSD
Ethereum
DBI
MDAX
MDAX
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
DBI
DAX
DAX
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten